Immune-mediated hemolytic anemia is a life-threatening emergency in dogs with significant welfare implications for both the acute crisis and long-term management of a relapsing condition.
IMHA welfare involves two distinct phases requiring different welfare approaches. The acute phase is a medical emergency where rapid intervention (transfusion if needed, immunosuppression initiation, supportive care) is essential to prevent death from severe anemia. Dogs in acute IMHA are experiencing oxygen deprivation at the cellular level, causing profound weakness and distress. The chronic management phase requires balancing the welfare benefit of disease control against the welfare costs of immunosuppression - increased infection risk, steroid side effects, and requirement for regular monitoring visits. Dogs that relapse require careful owner education to recognize early warning signs.